Anbio Biotechnology (FRA:N3B)

Market Cap	149.33M -85.8%
Revenue (ttm)	7.36M +5.6%
Net Income	5.45M +169.9%
EPS	0.13 +161.3%
Shares Out	n/a
PE Ratio	23.72
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	489
Open	3.220
Previous Close	3.140
Day's Range	3.100 - 3.220
52-Week Range	2.720 - 29.600
Beta	n/a
Analysts	n/a
Price Target	n/a
Est. Earnings	Apr 7, 2027

About Anbio Biotechnology

Anbio Biotechnology provides in vitro diagnostics (IVD) products in the European Union, the Asia Pacific, North America, South America, and internationally. The company offers lateral flow immunoassay, fluorescence immunoassay, loop-mediated isothermal amplification, SHA dry chemistry, chemiluminescence immunoassay, and real-time polymerase chain reaction solutions; and SARS-CoV-2 and SARS-CoV-2/Flu A/Flu B antigen rapid test kits. It serves over-the-counter, point-of-care testing, and laboratory markets. Anbio Biotechnology was incorporated in...

• Industry: Medical Instruments & Supplies
• Sector: Healthcare
• Founded: 2021
• Country: Cayman Islands
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: N3B

Financial Performance

In 2025, Anbio Biotechnology's revenue was $8.65 million, an increase of 5.64% compared to the previous year's $8.19 million. Earnings were $6.40 million, an increase of 169.86%.

Financial numbers in USD

Data Sources: S&P Global Market Intelligence and Twelve Data

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Twelve Data.

Last checked:

Oct 26, 2026

Data Sources Report a data error